On 20 September 2026, FIBOCOM (00638.HK) disclosed progress of a major asset restructuring to acquire 37.16% of Hangsheng Electronics and obtain 51.40% of its voting rights, having received the SAMR no-further-review decision.
On 21 September 2026, CUTIA-B (02487.HK) announced that CU-40102 (topical finasteride spray) received marketing approval in Macao for androgenetic alopecia, following earlier approvals in the Chinese mainland and Hong Kong.
On 20 September 2026, TRIGIANT (01300.HK) said its unit will buy Qinghai Zhongli Optical Fibre for RMB 455 million, RMB 310 million above the minimum bid.
On 18 September 2026, JUJIANG CONS (01459.HK) said it will sell 80% of a PPP company for RMB 66,312,601.14, expecting a pre-tax gain of RMB 29.7 million.
On 20 September 2026, TYK MEDICINES-B (02410.HK) said its agreement to issue 63,222,744 H shares lapsed at the long-stop date; Qilu agreed not to extend.
On 20 September 2026, DUIBA (01753.HK) said controlling shareholder Xiaoliang Holding gifted 120.68m shares, 11.21%, to Kewei Holding, control unchanged.
On 20 September 2026, CONCH MAT TECH (02560.HK) said a court froze 39m domestic shares, 6.73%, held by major shareholder Linyi Haihong until 17 September 2029.
On 18 September 2026, YUNFENG FIN (00376.HK) will sell Yunfeng Financial Markets to Yu Feng's Mega Investment for HKD 8,054,998, a connected transaction.
The HSI fell 0.22% while the HSTECH rose 1.97%; southbound net inflow hit HKD 12.01 billion. XIZHI TECH-P rose 22.61%, HQVT led weekly gains.
HK recently listed stocks diverged this week, with HQVT leading gains at 95.59% and Century Group International leading losses at 86.15%. Z.AI ranked first in liquidity with average daily turnover of approximately HK$8.30 billion. QIYUNSHAN FOOD led in deviation from issue price at 743.12%, while REFIRE recorded the deepest break below issue price at 94.45%. Next week, three recently listed stocks — NSING TECH, FS.COM and NEW VISION CO — will see lock-up expiries, totalling 32,372,800 shares.
On 18 September 2026, SHENYANG PUBLIC (00747.HK) announced the disposal of 100% equity interest in the target company, Shenzhen Jusheng Chuangjian Investment Development Co., Ltd., to Shenzhen Chengb Castle Century Trading Co., Ltd. at a consideration of RMB 2,000,000, with the purchaser wholly owned by Zhang Zehao.
On 18 September 2026, SF INTRA-CITY (09699.HK) announced that Lei Yanqun has resigned as a non-executive director of the Company with effect from the date of the announcement in order to devote more time to his other business commitments.
On 18 September 2026, NEWLINK TECH (09600.HK) announced that it entered into a termination agreement with the target company HK Ant Global Investment Co., Limited, its shareholders and beneficial owners to terminate the memorandum of intent on the acquisition of all shares of the target company, and the proposed acquisition will not proceed.
On 18 September 2026, LANCANG TEA (06911.HK) announced that its wholly-owned subsidiary Guangzhou Kangrui Lancang Ancient Tea entered into a supplementary working capital loan contract with Bank of China Guangzhou Liwan Sub-branch, extending a RMB 24.9 million loan by twelve months to 19 September 2027.
On 18 September 2026, TRANSTHERA-B (02617.HK) announced that its self-developed Jeentai® (tinengotinib) has been included in the CSCO Guidelines for the Diagnosis and Treatment of Biliary Tract Malignancies as a Class II recommendation, category 2A, for advanced biliary tract malignancies.
On 18 September 2026, IMAGI INT'L (00585.HK) announced that with effect from 18 September 2026, independent non-executive director Miao Xi ceased to be the chairman of the audit committee while remaining an independent non-executive director, and independent non-executive director Tam Man Hong has been appointed as the chairman of the audit committee.
